Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Reilly Website

Karlyne M. Reilly, Ph.D.

Selected Publications

1)  Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.
Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.
Phytochem Lett. 7: 42-45, 2014.
[Journal]
2)  Lockett S, Verma C, Brafman A, Gudla P, Nandy K, Mimaki Y, Fuchs PL, Jaja J, Reilly KM, Beutler J, Turbyville TJ.
Quantitative analysis of F-actin redistribution in astrocytoma cells treated with candidate pharmaceuticals.
Cytometry A. 2014.
[Journal]
3)  Reilly K.
Abate-Shen C, Politi K, Chodosh L, Olive K, eds.
Controlling Genetic Background in Crosses of Mouse Models of Cancer. In: Mouse Models of Cancer.
Cold Spring Harbor: Cold Spring Harbor Protocols; 2013. In Press. [Book Chapter]
4)  Reilly K.
Abate-Shen C, Politi K, Chodosh L, Olive K, eds.
The Effect of Genetic Background of Mouse Models of Human Cancer: Friend or Foe?. In: Mouse Models of Cancer.
Cold Spring Harbor: Cold Spring Harbor Protocols; 2013. In Press. [Book Chapter]
5)  Reilly K.
Abate-Shen C, Politi K, Chodosh L, Olive K, eds.
Using the Collaborative Cross to Study the Role of Genetic Diversity in Cancer-Related Phenotypes. In: Mouse Models of Cancer.
Cold Spring Harbor: Cold Spring Harbor Protocols; 2013. In Press. [Book Chapter]
6)  Jones G, Reilly K.
Upadhyaya M, Cooper D, eds.
Dissection of Complex Genetic and Epigenetic Interactions Underlying NF1 Cancer Susceptibility Using Mouse Models. In: Neurofirbomatosis Type 1.
Berlin: Springer-Verlag; 2013. In Press. [Book Chapter]
7)  Reilly KM.
Extending the convergence of canonical WNT signaling and classic cancer pathways for treatment of malignant peripheral nerve sheath tumors.
Cancer Discov. 3: 610-2, 2013.
[Journal]
8)  Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.
Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.
PLoS ONE. 8: e65801, 2013.
[Journal]
9)  Devkota KP, Wilson J, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.
Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth.
J. Nat. Prod. 76: 59-63, 2013.
[Journal]
10)  Amlin-Van Schaick JC, Kim S, Difabio C, Lee MH, Broman KW, Reilly KM.
Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.
Neuro-oncology. 14: 160-74, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 8/11/2014.